OrbusNeich Receives “Outstanding Globalization Award” at Gelonghui “Golden Awards” 2025

(Hong Kong, December 23, 2025) — OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, has won the “Outstanding Globalization Award” at the Gelonghui Annual “Golden Awards” for Outstanding Companies 2025. This accolade underscores the Group’s significant international presence and achievements in cross-border collaboration, driven by its forward-looking vision, innovation, and exceptional execution capabilities.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “For over two decades, we have been committed to developing innovative interventional solutions and building an integrated global network anchored by R&D, manufacturing, and logistics hubs in China, Japan, Germany, and the Netherlands to enhance supply chain resilience. Together with our robust commercial engine comprising 14 direct sales teams in Belgium, France, Germany, Hong Kong, Macau, Monaco, Indonesia, Japan, Malaysia, Netherlands, Singapore, Spain, Switzerland, and Taiwan and over 300 distributors, not only do we bring our high-quality and innovative interventional devices to over 70 countries and regions, but we also support Chinese medical device manufacturers in expanding internationally. We are honored to receive the recognition which reinforces our belief that deep cross-market integration is essential for sustainable business development.”

Gelonghui established the Annual “Golden Awards” for outstanding companies under the motto “Global Vision, Investing in China”. The awards aim to create the most authoritative rankings for listed and unicorn companies within the investment community. The selection encompasses all listed and unicorn companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, NYSE American, and NASDAQ. The “Outstanding Globalization Award” specifically honors companies that excel in efficiently allocating global resources. By leveraging capital connections, these companies have deeply integrated into international industrial chains, thereby enhancing the brand value, negotiation power, and industry influence of Chinese enterprises in the global market.

OrbusNeich has won the “Outstanding Globalization Award” at the Gelonghui annual “Golden Awards” for Outstanding Companies 2025.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.